TIFA: A Potential Drug Target Or Biomarker (G92610)

Target Name: TIFA

NCBI ID: G92610

TIFA

TIFA: A Potential Drug Target Or Biomarker

TIFA (TIFA_HUMAN), a protein that is expressed in various tissues of the human body, has been identified as a potential drug target or biomarker. TIFA is a cytoplasmic protein that is involved in the regulation of cell adhesion, and its dysfunction has been linked to various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The identification and characterization of TIFA as a potential drug target or biomarker began in the late 1990s, when researchers identified that TIFA was highly expressed in various tissues of the human body, including the brain, heart, liver, and pancreas. They also found that TIFA was involved in the regulation of cell adhesion, which is the process by which cells stick together to form tissues and organs.

TIFA is a transmembrane protein, which means that it spans the cell membrane and is involved in various cellular processes that occur within the cell. It is composed of a cytoplasmic region, a transmembrane region, and an intracellular region. The cytoplasmic region contains the protein's amino acids, while the transmembrane region spans the cell membrane and is responsible for TIFA's ability to interact with other molecules. The intracellular region is the part of the protein that interacts with inside the cell.

TIFA has been shown to play a role in many diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, TIFA has been shown to be involved in the development and progression of breast cancer. Researchers have found that TIFA is highly expressed in breast tissue and that its expression is associated with the development of breast cancer. They have also shown that TIFA inhibitors can be effective in treating breast cancer.

In addition to its involvement in cancer, TIFA has also been linked to the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Researchers have found that TIFA is highly expressed in the brain and that its expression is associated with the progression of neurodegenerative diseases. They have also shown that TIFA inhibitors can be effective in treating neurodegenerative diseases.

TIFA has also been linked to the development and progression of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. Researchers have found that TIFA is highly expressed in the immune system and that its expression is associated with the development of autoimmune disorders. They have also shown that TIFA inhibitors can be effective in treating autoimmune disorders.

In conclusion, TIFA is a protein that is involved in the regulation of cell adhesion and its dysfunction has been linked to various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, TIFA has emerged as a potential drug target or biomarker for a variety of therapeutic applications. Further research is needed to fully understand the role of TIFA in these diseases and to develop effective treatments.

Protein Name: TRAF Interacting Protein With Forkhead Associated Domain

Functions: Adapter molecule that plays a key role in the activation of pro-inflammatory NF-kappa-B signaling following detection of bacterial pathogen-associated molecular pattern metabolites (PAMPs) (PubMed:12566447, PubMed:15492226, PubMed:26068852, PubMed:28877472, PubMed:28222186, PubMed:30111836). Promotes activation of an innate immune response by inducing the oligomerization and polyubiquitination of TRAF6, which leads to the activation of TAK1 and IKK through a proteasome-independent mechanism (PubMed:15492226, PubMed:26068852). TIFA-dependent innate immune response is triggered by ADP-D-glycero-beta-D-manno-heptose (ADP-Heptose), a potent PAMP present in all Gram-negative and some Gram-positive bacteria: ADP-Heptose is recognized by ALPK1, which phosphorylates TIFA at Thr-9, leading to TIFA homooligomerization and subsequent activation of pro-inflammatory NF-kappa-B signaling (PubMed:30111836)

The "TIFA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TIFA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets